Osteonecrosis of the jaw during biyearly treatment with zoledronic acid for aromatase inhibitor associated bone loss in early breast cancer: A literature review

Osteonecrosis of the jaw (ONJ) is one of the most relevant and specific complication of biphosphonates. ONJ in patients receiving zoledronic acid every 3 to 4 weeks is frequently described, but the ONJ biyearly regimen used to reduce aromatase inhibitor associated bone loss (AIBL), is rarely reporte...

Descripción completa

Detalles Bibliográficos
Autores principales: Kourie, Hampig Raphael, Antoun, Joelle, El Rassy, Elie, Rassy, Marc, Sader-Ghorra, Claude, Kattan, Joseph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2015
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4648993/
https://www.ncbi.nlm.nih.gov/pubmed/26587372
http://dx.doi.org/10.1016/j.jbo.2015.09.001
_version_ 1782401293160022016
author Kourie, Hampig Raphael
Antoun, Joelle
El Rassy, Elie
Rassy, Marc
Sader-Ghorra, Claude
Kattan, Joseph
author_facet Kourie, Hampig Raphael
Antoun, Joelle
El Rassy, Elie
Rassy, Marc
Sader-Ghorra, Claude
Kattan, Joseph
author_sort Kourie, Hampig Raphael
collection PubMed
description Osteonecrosis of the jaw (ONJ) is one of the most relevant and specific complication of biphosphonates. ONJ in patients receiving zoledronic acid every 3 to 4 weeks is frequently described, but the ONJ biyearly regimen used to reduce aromatase inhibitor associated bone loss (AIBL), is rarely reported. A literature review, focusing on the important trials using zoledronic acid to reduce AIBL, found that the mean risk of developing ONJ when zoledronic acid is used biyearly varies between 0.12% and 0.7%.
format Online
Article
Text
id pubmed-4648993
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-46489932015-11-19 Osteonecrosis of the jaw during biyearly treatment with zoledronic acid for aromatase inhibitor associated bone loss in early breast cancer: A literature review Kourie, Hampig Raphael Antoun, Joelle El Rassy, Elie Rassy, Marc Sader-Ghorra, Claude Kattan, Joseph J Bone Oncol Review Article Osteonecrosis of the jaw (ONJ) is one of the most relevant and specific complication of biphosphonates. ONJ in patients receiving zoledronic acid every 3 to 4 weeks is frequently described, but the ONJ biyearly regimen used to reduce aromatase inhibitor associated bone loss (AIBL), is rarely reported. A literature review, focusing on the important trials using zoledronic acid to reduce AIBL, found that the mean risk of developing ONJ when zoledronic acid is used biyearly varies between 0.12% and 0.7%. Elsevier 2015-09-28 /pmc/articles/PMC4648993/ /pubmed/26587372 http://dx.doi.org/10.1016/j.jbo.2015.09.001 Text en © 2015 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Review Article
Kourie, Hampig Raphael
Antoun, Joelle
El Rassy, Elie
Rassy, Marc
Sader-Ghorra, Claude
Kattan, Joseph
Osteonecrosis of the jaw during biyearly treatment with zoledronic acid for aromatase inhibitor associated bone loss in early breast cancer: A literature review
title Osteonecrosis of the jaw during biyearly treatment with zoledronic acid for aromatase inhibitor associated bone loss in early breast cancer: A literature review
title_full Osteonecrosis of the jaw during biyearly treatment with zoledronic acid for aromatase inhibitor associated bone loss in early breast cancer: A literature review
title_fullStr Osteonecrosis of the jaw during biyearly treatment with zoledronic acid for aromatase inhibitor associated bone loss in early breast cancer: A literature review
title_full_unstemmed Osteonecrosis of the jaw during biyearly treatment with zoledronic acid for aromatase inhibitor associated bone loss in early breast cancer: A literature review
title_short Osteonecrosis of the jaw during biyearly treatment with zoledronic acid for aromatase inhibitor associated bone loss in early breast cancer: A literature review
title_sort osteonecrosis of the jaw during biyearly treatment with zoledronic acid for aromatase inhibitor associated bone loss in early breast cancer: a literature review
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4648993/
https://www.ncbi.nlm.nih.gov/pubmed/26587372
http://dx.doi.org/10.1016/j.jbo.2015.09.001
work_keys_str_mv AT kouriehampigraphael osteonecrosisofthejawduringbiyearlytreatmentwithzoledronicacidforaromataseinhibitorassociatedbonelossinearlybreastcanceraliteraturereview
AT antounjoelle osteonecrosisofthejawduringbiyearlytreatmentwithzoledronicacidforaromataseinhibitorassociatedbonelossinearlybreastcanceraliteraturereview
AT elrassyelie osteonecrosisofthejawduringbiyearlytreatmentwithzoledronicacidforaromataseinhibitorassociatedbonelossinearlybreastcanceraliteraturereview
AT rassymarc osteonecrosisofthejawduringbiyearlytreatmentwithzoledronicacidforaromataseinhibitorassociatedbonelossinearlybreastcanceraliteraturereview
AT saderghorraclaude osteonecrosisofthejawduringbiyearlytreatmentwithzoledronicacidforaromataseinhibitorassociatedbonelossinearlybreastcanceraliteraturereview
AT kattanjoseph osteonecrosisofthejawduringbiyearlytreatmentwithzoledronicacidforaromataseinhibitorassociatedbonelossinearlybreastcanceraliteraturereview

Ejemplares similares